These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 23682862)

  • 21. ▼Teriflunomide for multiple sclerosis.
    Drug Ther Bull; 2014 Jul; 52(7):81-4. PubMed ID: 25012149
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Teriflunomide for the treatment of relapsing-remitting multiple sclerosis.
    Miller AE
    Expert Rev Clin Immunol; 2015 Feb; 11(2):181-94. PubMed ID: 25511008
    [TBL] [Abstract][Full Text] [Related]  

  • 23. What's new about oral treatments in Multiple Sclerosis? Immunogenetics still under question.
    Pistono C; Osera C; Boiocchi C; Mallucci G; Cuccia M; Bergamaschi R; Pascale A
    Pharmacol Res; 2017 Jun; 120():279-293. PubMed ID: 28396093
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Teriflunomide added to interferon-β in relapsing multiple sclerosis: a randomized phase II trial.
    Freedman MS; Wolinsky JS; Wamil B; Confavreux C; Comi G; Kappos L; Olsson TP; Miller A; Benzerdjeb H; Li H; Simonson C; O'Connor PW;
    Neurology; 2012 Jun; 78(23):1877-85. PubMed ID: 22622860
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Leflunomide and teriflunomide: altering the metabolism of pyrimidines for the treatment of autoimmune diseases.
    Fragoso YD; Brooks JB
    Expert Rev Clin Pharmacol; 2015 May; 8(3):315-20. PubMed ID: 25712857
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Teriflunomide for the treatment of relapsing multiple sclerosis: a review of clinical data.
    Brunetti L; Wagner ML; Maroney M; Ryan M
    Ann Pharmacother; 2013 Sep; 47(9):1153-60. PubMed ID: 24259730
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Oral disease-modifying agents in relapsing-remitting multiple sclerosis].
    Iljicsov A; Pál Z; Simó M
    Neuropsychopharmacol Hung; 2015 Dec; 17(4):197-205. PubMed ID: 26727724
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tolerability and efficacy of colestipol hydrochloride for accelerated elimination of teriflunomide.
    Robertson D; Dixon C; Aungst A; McCoy B; Moreo N; Casady L; Maldonado J
    Expert Rev Clin Pharmacol; 2017 Dec; 10(12):1403-1407. PubMed ID: 29064296
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Alemtuzumab and teriflunomide approved].
    Fischer S
    Med Monatsschr Pharm; 2013 Oct; 36(10):393-4. PubMed ID: 24266250
    [No Abstract]   [Full Text] [Related]  

  • 30. Spotlight on teriflunomide.
    Tallantyre E; Evangelou N; Constantinescu CS
    Int MS J; 2008 Jun; 15(2):62-8. PubMed ID: 18782502
    [TBL] [Abstract][Full Text] [Related]  

  • 31. LC-MS/MS Method for the Quantification of the Leflunomide Metabolite, Teriflunomide, in Human Serum/Plasma.
    Rule GS; Rockwood AL; Johnson-Davis KL
    Methods Mol Biol; 2019; 1872():75-83. PubMed ID: 30350281
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Magnetic resonance imaging outcomes from a phase III trial of teriflunomide.
    Wolinsky JS; Narayana PA; Nelson F; Datta S; O'Connor P; Confavreux C; Comi G; Kappos L; Olsson TP; Truffinet P; Wang L; Miller A; Freedman MS;
    Mult Scler; 2013 Sep; 19(10):1310-9. PubMed ID: 23447359
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nanostructured lipid carriers engineered for intranasal delivery of teriflunomide in multiple sclerosis: optimization and in vivo studies.
    Gadhave DG; Kokare CR
    Drug Dev Ind Pharm; 2019 May; 45(5):839-851. PubMed ID: 30702966
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Oral treatment for multiple sclerosis.
    Killestein J; Rudick RA; Polman CH
    Lancet Neurol; 2011 Nov; 10(11):1026-34. PubMed ID: 22014437
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Profiling of dihydroorotate dehydrogenase, p38 and JAK inhibitors in the rat adjuvant-induced arthritis model: a translational study.
    Balagué C; Pont M; Prats N; Godessart N
    Br J Pharmacol; 2012 Jun; 166(4):1320-32. PubMed ID: 22229697
    [TBL] [Abstract][Full Text] [Related]  

  • 36. COVID-19 in teriflunomide-treated patients with multiple sclerosis: A case report and literature review.
    Capone F; Motolese F; Luce T; Rossi M; Magliozzi A; Di Lazzaro V
    Mult Scler Relat Disord; 2021 Feb; 48():102734. PubMed ID: 33429305
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pre-specified subgroup analyses of a placebo-controlled phase III trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosis.
    Miller AE; O'Connor P; Wolinsky JS; Confavreux C; Kappos L; Olsson TP; Truffinet P; Wang L; D'Castro L; Comi G; Freedman MS;
    Mult Scler; 2012 Nov; 18(11):1625-32. PubMed ID: 22723573
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Oral treatments in multiple sclerosis].
    Meca-Lallana JE; Hernández-Clares R; Carreón-Guarnizo E
    Med Clin (Barc); 2014 Dec; 143 Suppl 3():23-9. PubMed ID: 25732946
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term safety and efficacy of teriflunomide: Nine-year follow-up of the randomized TEMSO study.
    O'Connor P; Comi G; Freedman MS; Miller AE; Kappos L; Bouchard JP; Lebrun-Frenay C; Mares J; Benamor M; Thangavelu K; Liang J; Truffinet P; Lawson VJ; Wolinsky JS;
    Neurology; 2016 Mar; 86(10):920-30. PubMed ID: 26865517
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New oral drugs for multiple sclerosis.
    Gasperini C; Ruggieri S
    Neurol Sci; 2009 Oct; 30 Suppl 2():S179-83. PubMed ID: 19882371
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.